{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:03:00Z","timestamp":1778540580681,"version":"3.51.4"},"reference-count":39,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>To obtain information on the transport of valproic acid from mothers to colostrum and breastfed infants, in this cohort study, valproic acid concentrations in maternal serum (90 subjects), colostrum and the serum of breastfed infants were analyzed in years 1993\u20132018, between the 2nd and 5th postnatal days. Valproic acid concentrations ranged from 4.3 to 66.5 mg\/L (mean 31.2 \u00b1 13.6 mg\/L) in maternal serum, from 0.5 to 5.9 mg\/L (mean 1.1 \u00b1 1.2 mg\/L) in milk, and from 0.5 to 42.9 mg\/L (mean 15.4 \u00b1 9.4 mg\/L) in infant serum. The milk\/maternal serum concentration ratio ranged from 0.01 to 0.22 (mean 0.04 \u00b1 0.04), and the infant\/maternal serum concentration ratio ranged from 0.01 to 1.61 (mean 0.51 \u00b1 0.28). A significant correlation was found between serum concentrations of breastfed infants and milk concentrations, maternal serum concentrations, maternal daily dose, and dose related to maternal body weight. Valproic acid concentrations in milk and infant serum did not reach the lower limit of the reference range used for the general epileptic population, and three-quarters of the concentrations in milk were lower than the lower limit of quantification. Routine monitoring of serum concentrations of breastfed infants is not necessary. If signs of potential adverse reactions are noted, serum concentrations of the infants should be measured.<\/jats:p>","DOI":"10.3390\/pharmaceutics13122074","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T03:10:38Z","timestamp":1638760238000},"page":"2074","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Valproic Acid Concentrations in Mothers, Colostrum and Breastfed Infants during the Early Postpartum Period: Comparison with Concentrations Determined during Delivery and in the Mature Milk Period"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6618-754X","authenticated-orcid":false,"given":"Ivana","family":"Kacirova","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic"},{"name":"Department of Laboratory Medicine, Institute of Clinical Pharmacology, University Hospital Ostrava, 70852 Ostrava, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2410-0455","authenticated-orcid":false,"given":"Milan","family":"Grundmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic"},{"name":"Department of Laboratory Medicine, Institute of Clinical Pharmacology, University Hospital Ostrava, 70852 Ostrava, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Brozmanova","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic"},{"name":"Department of Laboratory Medicine, Institute of Clinical Pharmacology, University Hospital Ostrava, 70852 Ostrava, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"ref_1","first-page":"CD010224","article-title":"Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child","volume":"11","author":"Weston","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e186606","DOI":"10.1001\/jamanetworkopen.2018.6606","article-title":"Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs with Risk for Attention-Deficit\/Hyperactivity Disorder in Offspring","volume":"2","author":"Christensen","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jamaneurol.2017.5035","article-title":"Association Between Prenatal Valproate Exposure and Performance on Standardized Language and Mathematics Tests in School-aged Children","volume":"75","author":"Bech","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/ane.13397","article-title":"Valproic acid and socioeconomic associations in Swedish women with epilepsy 2010\u20132015","volume":"143","author":"Andersson","year":"2021","journal-title":"Acta Neurol. Scand."},{"key":"ref_5","unstructured":"(2021, October 15). New Measures to Avoid Valproate Exposure in Pregnancy Endorsed. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/valproate-related-substances-0."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/epi.16407","article-title":"Doing without valproate in women of childbearing potential with idiopathic generalized epilepsy: Implication on seizure outcome","volume":"61","author":"Irelli","year":"2020","journal-title":"Epilepsia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1212\/WNL.0000000000008001","article-title":"Declining malformation rates with changed antiepileptic drug prescribing: An observational study","volume":"93","author":"Tomson","year":"2019","journal-title":"Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/epi.16505","article-title":"Pregnancy after valproate withdrawal\u2014Fetal malformations and seizure control","volume":"61","author":"Vajda","year":"2020","journal-title":"Epilepsia"},{"key":"ref_9","first-page":"23","article-title":"Trend analysis of the utilization of antiepileptic drugs in pregnant women with epilepsy in Mo-ravian-Silesian region of the Czech Republic","volume":"30","author":"Kacirova","year":"2016","journal-title":"Klin. Farmakol. Farm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/jnnp-2017-317368","article-title":"Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations","volume":"89","author":"Kinney","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/epi.16882","article-title":"Valproate usage in pregnancy: An audit from the Kerala Registry of Epilepsy and Pregnancy","volume":"62","author":"Seshachala","year":"2021","journal-title":"Epilepsia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.eplepsyres.2017.10.012","article-title":"Contraception, pregnancy, and peripartum experiences among women with epilepsy in Bhutan","volume":"138","author":"Halani","year":"2017","journal-title":"Epilepsy Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.yebeh.2015.07.011","article-title":"Epilepsy care in the southern Caribbean","volume":"51","author":"Krauss","year":"2015","journal-title":"Epilepsy Behav."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.5507\/bp.2015.055","article-title":"Serum levels of valproic acid during delivery in mothers and in umbilical cord\u2014Correlation with birth length and weight","volume":"159","author":"Kacirova","year":"2015","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.yebeh.2019.04.002","article-title":"Valproic acid concentrations in nursing mothers, mature milk, and breastfed infants in monotherapy and combination therapy","volume":"95","author":"Kacirova","year":"2019","journal-title":"Epilepsy Behav."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaneurol.2019.4443","article-title":"Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers with Epilepsy","volume":"77","author":"Birnbaum","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e00131","DOI":"10.1002\/prp2.131","article-title":"Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses","volume":"3","author":"Keizer","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yebeh.2014.02.011","article-title":"Carbamazepine clearance and seizure stability during pregnancy","volume":"33","author":"Johnson","year":"2014","journal-title":"Epilepsy Behav."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00007691-198409000-00003","article-title":"Valproic Acid in Breast Milk: How Much Is Really There?","volume":"6","author":"Froescher","year":"1984","journal-title":"Ther. Drug Monit."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0022-3476(84)80567-3","article-title":"Valproic acid in the perinatal period: Decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites","volume":"104","author":"Nau","year":"1984","journal-title":"J. Pediatr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4088\/JCP.v61n0304","article-title":"Serum valproate levels in 6 breastfeeding mother-infant pairs","volume":"61","author":"Piontek","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"ref_23","first-page":"768","article-title":"Valproic acid and its metabolites: Placental transfer, neonatal pharmacoki-netics, transfer via mother\u2019s milk and clinical status in neonates of epileptic mothers","volume":"219","author":"Nau","year":"1981","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_24","unstructured":"Dam, M. (1981). Antiepileptic Therapy with Carbamazepine and Valproic Acid During Pregnancy and Lactation Period. Advances in Epileptology: XIIth Epilepsy International Symposium, Raven Press."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1600-0404.1985.tb00901.x","article-title":"Concentration of valproate during pregnancy, in the newborn and in breast milk","volume":"72","author":"Philbert","year":"1985","journal-title":"Acta Neurol. Scand."},{"key":"ref_26","first-page":"1195","article-title":"The perinatal pharmacokinetics of anticonvulsant drugs","volume":"110","author":"Meyer","year":"1988","journal-title":"Zent. Gynakol"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1542\/peds.104.1.e11","article-title":"Serum concentrations of antidepressants and benzodiazepines in nursing infants: A case series","volume":"104","author":"Birnbaum","year":"1999","journal-title":"Pediatrics"},{"key":"ref_28","first-page":"89","article-title":"Three Cases of Delivery under Sodium Valproate\u2014Placental Transfer, Milk Transfer and Probable Teratogenicity of Sodium Valproate","volume":"42","author":"Tsuru","year":"1988","journal-title":"Jpn. J. Psychiatry Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00004714-199804000-00009","article-title":"Serum Levels of Valproate and Carbamazepine in Breastfeeding Mother-Infant Pairs","volume":"18","author":"Wisner","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0022-3476(79)80172-9","article-title":"Transmission of valproic acid (Depakene) across theplacenta: Half-life of the drug in mother and baby","volume":"94","author":"Dickinson","year":"1979","journal-title":"J. Pediatr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/adc.54.3.240","article-title":"Sodium valproate and pregnancy","volume":"54","author":"Alexander","year":"1979","journal-title":"Arch. Dis. Child."},{"key":"ref_32","unstructured":"Janz, D., Bossi, L., Dam, M., Helge, H., Richens, A., and Schmidt, D. (1982). Valproic Acid and Breast-Feeding. Epilepsy, Pregnancy and The Child, Raven Press."},{"key":"ref_33","unstructured":"Legg, N.J. (1976). Sodium Valproate (Epilim)-Some Clinical and Pharmacological Aspects. Clinical and Pharmacological Aspects of Sodium Valproate in The Treatment of Epilepsy: Proceedings of a Symposium, MCS Consultants."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0022-3476(97)70292-0","article-title":"Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid","volume":"130","author":"Stahl","year":"1997","journal-title":"J. Pediatr."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kacirova, I., Grundmann, M., and Brozmanova, H. (2021). Umbilical Cord, Maternal Milk, and Breastfed Infant Levetiracetam Concentrations Monitoring at Delivery and during Early Postpartum Period. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13030398"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"111446","DOI":"10.1016\/j.biopha.2021.111446","article-title":"Monitoring topiramate concentrations at delivery and during lactation","volume":"138","author":"Kacirova","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00204-014-1224-8","article-title":"Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics","volume":"88","author":"Jani","year":"2014","journal-title":"Arch. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"E1172","DOI":"10.1152\/ajpendo.00381.2001","article-title":"Peptide transport in the mammary gland: Expression and distribution of PEPT2 mRNA and protein","volume":"282","author":"Groneberg","year":"2002","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Lino, A.M., \u00c1lvarez-Fern\u00e1ndez, I., Blanco-Paniagua, E., Merino, G., and \u00c1lvarez, A.I. (2019). Transporters in the Mammary Gland\u2014Contribution to Presence of Nutrients and Drugs into Milk. Nutrients, 11.","DOI":"10.3390\/nu11102372"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/2074\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:39:37Z","timestamp":1760168377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/2074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["pharmaceutics13122074"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13122074","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]}}}